ResearcherHospital Universitari i Politècnic La FeActive in the last 2 years

Carlos Escriva-Aranda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-6851-8160; OpenAlex author ID A5138885159. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2026: 1 paper

Papers 1

Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1177/17588359261456797 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jorge Aparicio · 1 shared paper, 2026 · strength 0.28
- Paper Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic … DOI 10.1177/17588359261456797 ↗
Robert Díaz Beveridge · 1 shared paper, 2026 · strength 0.28
- Paper Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic … DOI 10.1177/17588359261456797 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.